TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23143294

Group type: EXPERIMENTAL
Intervention: Survivors of pediatric brain tumors
Number of subjects: 78

Group type: COMPARATOR
Intervention: Population-based controls
Number of subjects: 78
Study: 21132025

Group type: EXPERIMENTAL
Intervention: 12-week outpatient physical exercise program (PE), incorporating aerobic and strength exercises.
Number of subjects: 131

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 131
Study: 18752540

Group type: EXPERIMENTAL
Intervention: WoundCare 18+ (Manuka honey)
Number of subjects: 108

Group type: COMPARATOR
Intervention: IntraSite Gel (hydrogel)
Number of subjects: 108
Study: 16863588

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive therapy (Control)
Number of subjects: 0
Study: 12624570

Group type: EXPERIMENTAL
Intervention: Dietary intervention to lower saturated fat and cholesterol intake
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 11069572

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) - beclomethasone dipropionate 200 microg or budesonide 200 microg, prescribed twice daily
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group - beta2-agonist only
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Combined health care costs in the ICS group
Number of subjects: 86
Study: 9235813

Group type: EXPERIMENTAL
Intervention: Piroxicam-beta-cyclodextrin 20 mg daily for 14 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Piroxicam 20 mg daily for 14 days
Number of subjects: 32
Study: 1441691

Group type: EXPERIMENTAL
Intervention: slow-release gallopamil, 100 mg b.i.d.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: slow-release nifedipine, 20 mg b.i.d.
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 3896014

Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pethidine
Number of subjects: 48
Study: 31115611

Group type: EXPERIMENTAL
Intervention: POP repair with mesh
Number of subjects: 255
Study: 29570019

Group type: EXPERIMENTAL
Intervention: SP-DW (sodium perborate-distilled water mixture)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: SP-HP (sodium perborate-3% hydrogen peroxide mixture)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: CP (37% carbamide peroxide gel)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: HP (35% H2O2 gel)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (no bleaching agent)
Number of subjects: 125
Study: 26522140

Group type: EXPERIMENTAL
Intervention: Preoperative misoprostol (400μg, given rectally)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Postoperative misoprostol (400μg, given rectally)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Both groups (preoperative and postoperative misoprostol)
Number of subjects: 348
Study: 24732494

Group type: EXPERIMENTAL
Intervention: Training on the Raven robot
Number of subjects: 30

Group type: COMPARATOR
Intervention: Training on the da Vinci robot
Number of subjects: 30
Study: 22874536

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) - 12 weeks, 3 sets, 10 exercises, 3 times per week, 8-12 repetition maximum (RM)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Social Interaction (SI) - stretching, knitting, health lectures, 2 times per week (Control Group)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Single Resistance Exercise (RE) bout
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control Group (CON)
Number of subjects: 23
Study: 20143387

Group type: EXPERIMENTAL
Intervention: Dual direction k space traversal with maintained diffusion-encoding gradient strength and direction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distortion correction routine applied to SE-EPI fMRI acquisitions
Number of subjects: 0
Study: 18661839

Group type: EXPERIMENTAL
Intervention: gengnianningshentang
Number of subjects: 108

Group type: COMPARATOR
Intervention: Vitamin E
Number of subjects: 108
Study: 15701463

Group type: COMPARATOR
Intervention: Noninvasive pacemaker stress echocardiography (PASE)
Number of subjects: 26
Study: 11858475

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin, dalteparin (N = 21) once daily subcutaneously
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Unfractionated sodium heparin (UF heparin, N = 23) twice daily subcutaneously
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (healthy, delivered women, N = 19)
Number of subjects: 44
Study: 10074877

Group type: EXPERIMENTAL
Intervention: Clozapine (maximum dose of 300 mg/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Chlorpromazine (maximum dose of 600 mg/day)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Clozapine and Chlorpromazine
Number of subjects: 42
Study: 7493417

Group type: EXPERIMENTAL
Intervention: Inspiratory gasp
Number of subjects: 0
Study: 2024753

Group type: EXPERIMENTAL
Intervention: Lignocaine 1.5% with 1/200,000 adrenaline (group L)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Prilocaine 1.5% plain (group P)
Number of subjects: 20
Study: 7215756

Group type: EXPERIMENTAL
Intervention: Calcium heparin (7,500 i.u. subcutaneous twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semi-synthetic heparin analogue (5,000 U subcutaneous twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 0
Study: 30591535

Group type: EXPERIMENTAL
Intervention: Low-dose CT (LDCT) lung cancer screening
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Volume doubling time (VDT) and volume assessment
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: VDT ≤590 days or volume ≥200 mm3
Number of subjects: 680
Study: 25581063

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 0
Study: 23821379

Group type: EXPERIMENTAL
Intervention: Multimodal psychosocial rehabilitation intervention (three supportive talks and a residential rehabilitation course)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Usual services (control group)
Number of subjects: 42
Study: 21653307

Group type: COMPARATOR
Intervention: Standard counseling (2 sessions)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Enhanced counseling (5 sessions)
Number of subjects: 457

Group type: COMPARATOR
Intervention: Riskier group (standard counseling)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Riskier group (enhanced counseling)
Number of subjects: 457
Study: 19775999

Group type: EXPERIMENTAL
Intervention: Radiation therapy after breast-conserving surgery (BCS)
Number of subjects: 42000

Group type: EXPERIMENTAL
Intervention: Radiation therapy after complete mastectomy
Number of subjects: 42000

Group type: COMPARATOR
Intervention: Breast conservative surgery without radiation therapy
Number of subjects: 42000
Study: 16054822

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass
Number of subjects: 0

Group type: COMPARATOR
Intervention: No cardiopulmonary bypass
Number of subjects: 0
Study: 12185328

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiation therapy (PMRT)
Number of subjects: 0
Study: 11072419

Group type: EXPERIMENTAL
Intervention: Caffeine 200 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Caffeine 400 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Caffeine 0 mg (placebo)
Number of subjects: 14
Study: 7793647

Group type: COMPARATOR
Intervention: 0.5% bupivacaine (150 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine (150 mg)
Number of subjects: 60
Study: 1903598

Group type: EXPERIMENTAL
Intervention: Growth hormone infusion (45 ng.kg‐1.min‐1)
Number of subjects: 7
Study: 7017100

Group type: EXPERIMENTAL
Intervention: Droperidol (0.05 mg/kg, intravenously administered)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 31640997

Group type: EXPERIMENTAL
Intervention: ABM+real tDCS
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: ABM+sham tDCS
Number of subjects: 66

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 66
Study: 27875017

Group type: EXPERIMENTAL
Intervention: Gum chewing and semi-liquid diet
Number of subjects: 234

Group type: COMPARATOR
Intervention: Semi-liquid only diet
Number of subjects: 234

Group type: COMPARATOR
Intervention: Liquid diet
Number of subjects: 234
Study: 26443659

Group type: EXPERIMENTAL
Intervention: 5 minutes of tailored brief advice delivered by dental practitioners during the patient's appointment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 12
Study: 23373664

Group type: EXPERIMENTAL
Intervention: Partial directly observed antiretroviral therapy (DOT‐ART)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Self‐administered ART (Self‐ART)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Both DOT‐ART and Self‐ART
Number of subjects: 172
Study: 21447934

Group type: COMPARATOR
Intervention: Noninvasive positive pressure ventilation (NPPV) by mask
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation (NPPV) by helmet
Number of subjects: 53
Study: 20031735

Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine (2 x 120 microg in 20 mL NaCl)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Placebo (2 x 20 mL NaCl)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine
Number of subjects: 448

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 448
Study: 17352768

Group type: EXPERIMENTAL
Intervention: IL-2 (7.5 MIU twice a day, for 5 days every 8 weeks)
Number of subjects: 1673
Study: 15028250

Group type: EXPERIMENTAL
Intervention: (99m)Tc‐UBI
Number of subjects: 6
Study: 12365878

Group type: EXPERIMENTAL
Intervention: ethyl-eicosapentaenoate 1 g/d
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: ethyl-eicosapentaenoate 2 g/d
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: ethyl-eicosapentaenoate 4 g/d
Number of subjects: 70

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 70
Study: 9521435

Group type: EXPERIMENTAL
Intervention: Beta-carotene and vitamin A supplementation (30 mg of beta-carotene and 25,000 IU of retinyl palmitate)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Beta-carotene and vitamin A supplementation
Number of subjects: 21
Study: 7855556

Group type: EXPERIMENTAL
Intervention: Imipenem (Imi)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Combination of tobramycin and cefuroxime (T/C)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Vancomycin and aztreonam (V/A)
Number of subjects: 91
Study: 2535678

Group type: EXPERIMENTAL
Intervention: nisoldipine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: usual anti-hypertensive therapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: control population
Number of subjects: 12

Group type: COMPARATOR
Intervention: untreated hypertensive patients
Number of subjects: 12
Study: 1096127

Group type: EXPERIMENTAL
Intervention: Intravenous salbutamol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous aminophylline
Number of subjects: 20
Study: 31917100

Group type: EXPERIMENTAL
Intervention: 3 mg/kg/day of ferrous sulfate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31682619

Group type: EXPERIMENTAL
Intervention: Using mobile phone
Number of subjects: 125

Group type: COMPARATOR
Intervention: Sitting alone with no phone
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Resisting the phone
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Sitting with device but resisting use
Number of subjects: 125
Study: 28529147

Group type: EXPERIMENTAL
Intervention: norUDCA 500mg/d
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: norUDCA 1000mg/d
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: norUDCA 1500mg/d
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 25592163

Group type: EXPERIMENTAL
Intervention: LOCI intervention (6-month duration)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Two-session leadership webinar control
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: LOCI intervention
Number of subjects: 100
Study: 23760736

Group type: EXPERIMENTAL
Intervention: Partial Sleep Deprivation (PSD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal Sleep (Norm)
Number of subjects: 10
Study: 21711174

Group type: EXPERIMENTAL
Intervention: Soy (2 mg/kg body weight aglycone equivalent isoflavones)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of seaweed (5 g/day) and soy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 18064563

Group type: EXPERIMENTAL
Intervention: Fluoxetine (daily oral for 6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16271911

Group type: EXPERIMENTAL
Intervention: Workshop and decision tree
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Workshop
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Decision tree
Number of subjects: 249

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 249
Study: 12665914

Group type: EXPERIMENTAL
Intervention: Lamivudine + Thymopentin (Group A)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Lamivudine (Group B)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Thymopentin (Group C)
Number of subjects: 98
Study: 9655431

Group type: COMPARATOR
Intervention: Intact hair follicles (control group A; n = 100)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Lower-half hair follicles (experimental group B; n = 200)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Upper-half hair follicles (experimental group B; n = 200)
Number of subjects: 300
Study: 8600607

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg twice daily
Number of subjects: 83

Group type: COMPARATOR
Intervention: Atenolol 50 mg daily
Number of subjects: 83
Study: 2510562

Group type: EXPERIMENTAL
Intervention: Flumazenil (1 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1117287

Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trifluoperazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: No drug
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31726093

Group type: EXPERIMENTAL
Intervention: Microsurgery without arthrodesis
Number of subjects: 50
Study: 29127472

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) group
Number of subjects: 600

Group type: COMPARATOR
Intervention: No atrial fibrillation (non-AF) group
Number of subjects: 600
Study: 26009003

Group type: EXPERIMENTAL
Intervention: High-intensity games intervention (twice-weekly, 40 min sessions for 6 weeks)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: High-intensity games intervention (for obese participants)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 55
Study: 25591636

Group type: EXPERIMENTAL
Intervention: XR‐NTX (380 mg)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 22814409

Group type: EXPERIMENTAL
Intervention: Anthrax Vaccine Adsorbed (AVA)
Number of subjects: 1562

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 1562

Group type: COMPARATOR
Intervention: Reduced AVA schedule with saline placebo
Number of subjects: 1562
Study: 20817409

Group type: EXPERIMENTAL
Intervention: BLING intervention
Number of subjects: 1846
Study: 18680075

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (0.1 mg bolus, then 35 microg/kg/min for 6 hours, maximum dose 9 mg)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin
Number of subjects: 208
Study: 15647969

Group type: EXPERIMENTAL
Intervention: 200 IU intranasal salmon calcitonin (Miacalcic nasal 200) daily, 1 month on-1 month off, 0.25 mug 1alpha(OH)D3, and 500 mg elemental calcium continuously
Number of subjects: 102

Group type: COMPARATOR
Intervention: 0.25 mug 1alpha(OH)D3 and 500 mg elemental calcium
Number of subjects: 102
Study: 12034414

Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor antagonists
Number of subjects: 12110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12110

Group type: EXPERIMENTAL
Intervention: Losartan (reference drug)
Number of subjects: 12110
Study: 9529169

Group type: EXPERIMENTAL
Intervention: Operative abdominal decompression
Number of subjects: 11
Study: 8017601

Group type: EXPERIMENTAL
Intervention: Oral clonidine 300 micrograms
Number of subjects: 34

Group type: COMPARATOR
Intervention: Oral diazepam 10 mg
Number of subjects: 34
Study: 2513967

Group type: EXPERIMENTAL
Intervention: Dementia carers' programme
Number of subjects: 96

Group type: COMPARATOR
Intervention: Memory retraining programme
Number of subjects: 96

Group type: COMPARATOR
Intervention: Wait list group
Number of subjects: 96
Study: 9752388

Group type: EXPERIMENTAL
Intervention: Therapeutic mixture containing 10 mg of methylphenidate, 2.5 mg of methandrostenolone, and a mixture of B vitamins
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 28857996

Group type: EXPERIMENTAL
Intervention: Suturation plus Surgicel application (Group 1)
Number of subjects: 760

Group type: COMPARATOR
Intervention: Control (Group 2)
Number of subjects: 760
Study: 25775686

Group type: EXPERIMENTAL
Intervention: Ultrasound-accelerated thrombolysis (UST)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard thrombolysis (ST)
Number of subjects: 60
Study: 24088419

Group type: EXPERIMENTAL
Intervention: Tailored Physical Activity (three 50-minute sessions per week over 10 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health Guidance (90-minute individualised dialogue)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tailored Physical Activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health Guidance
Number of subjects: 0
Study: 21418585

Group type: EXPERIMENTAL
Intervention: KRTE only (KO)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Acupuncture only (AO)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: KRTE and acupuncture combined (KA)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Waiting list group (WL)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: All groups (KO, AO, KA, WL)
Number of subjects: 44
Study: 18955563

Group type: EXPERIMENTAL
Intervention: Thalidomide-dexamethasone (TD)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Melphalan-prednisolone (MP)
Number of subjects: 289
Study: 17996140

Group type: EXPERIMENTAL
Intervention: Percutaneous thrombectomy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 68
Study: 15475141

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 0.05 mg/kg/day
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 11501649

Group type: EXPERIMENTAL
Intervention: Nickel sulfate patch test
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Potassium dichromate patch test
Number of subjects: 589
Study: 9603111

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 40
Study: 7921095

Group type: EXPERIMENTAL
Intervention: Cefpodoxime for 10 days
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Cefpodoxime for 5 days
Number of subjects: 484

Group type: COMPARATOR
Intervention: Penicillin V for 10 days
Number of subjects: 484
Study: 30110336

Group type: EXPERIMENTAL
Intervention: DIABSCORE ≥ 90
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: DIABSCORE ≥ 80
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: ROC curves for T2D
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: ROC curves for prediabetes
Number of subjects: 225
Study: 29947487

Group type: EXPERIMENTAL
Intervention: Intraperitoneal bupivacaine (40 ml of 0.25% solution)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 62
Study: 23884391

Group type: EXPERIMENTAL
Intervention: LogMAR visual acuity
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Pelli Robson contrast sensitivity
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: LogMAR reading acuity
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Reading speed
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: LogMAR critical print size
Number of subjects: 83
Study: 22285109

Group type: EXPERIMENTAL
Intervention: Empiric systemic anticoagulation (ESA)
Number of subjects: 7932

Group type: COMPARATOR
Intervention: No empiric systemic anticoagulation (ESA)
Number of subjects: 7932
Study: 20450425

Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA) with 400 mg ropivacaine, 30 mg ketorolac, and 0.5 mg epinephrine during operation and 200 mg ropivacaine, 30 mg ketorolac, and 0.1 mg epinephrine 21 h postoperatively
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group with no injections during operation and saline injection 21 h postoperatively
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA)
Number of subjects: 48
Study: 18481390

Group type: EXPERIMENTAL
Intervention: Oregovomab immunotherapy
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 16527015

Group type: EXPERIMENTAL
Intervention: Tisseel (2 cc)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 12660408

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CrH2O) supplementation (0.5 g x kg(‐1) FFM, one fourth dosage 4 times daily for 5 days)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 10962639

Group type: EXPERIMENTAL
Intervention: Pre‐sacral neurectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Uterosacral ligament resection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adhesiolysis
Number of subjects: 0